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Abstract
Background: All authorities recommend against prostate specific antigen (PSA) screening in men 75 years and
older. However, some primary care physicians (PCPs) continue to have high rates of PSA, with large variation in
testing. We assessed the tests, treatments, and payments for prostate cancer care in men aged 75 or older who
have PCPs with high or low PSA testing rates.
Methods: We performed a retrospective cohort study using the 2010 Medicare beneficiaries aged 75 or older in
Texas, United States who had no prostate cancer in 2007–2009 and had an identifiable PCP. We first identified high
vs. low PSA testing PCPs, and then grouped older men in the two PCP groups. We determined health care visits to
any provider and to urologists in office and outpatient settings. We estimated the direct medical payments for
prostate cancer care for diagnostics, treatments and visits to providers in 2010–2011 using the generalized gamma
model with log link function.
Results: In multilevel, multivariable analyses, 25.4 % (n = 550) of PCPs had PSA testing rates in men aged 75 or
older that were significantly higher than the mean rate of all 2,169 Texas PCPs; 29.4 % (n = 638) had rates that were
significantly lower. In all, 22,853 vs. 23,929 older men were cared for by PCPs with high vs. low testing rates. Older
men cared for by high PSA rate PCPs were more likely to receive a PSA test (OR 3.64, 95 % CI 3.48–3.80), a biopsy
(OR 1.16, 95 % CI 1.02–1.31), an ultrasound (OR 1.19, 95 % CI 1.07–1.32) or any radiation treatment (OR 1.31, 95 % CI
1.03–1.66) than men cared for by low PSA rate PCPs. Men with high PSA rate PCPs were 1.21 (95 % CI 1.05–1.39)
times more likely to have such outpatient visits. The average annual adjusted Medicare payments for prostate
cancer care was $25.60 higher for patients cared for by PCPs with high PSA test rates.
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Conclusions: Older men seeing PCPs with high rates of PSA testing undergo more testing and treatments for
prostate cancer, with higher Medicare insurance payments. Future studies are needed to delineate whether men
seeing PCPs with low testing rates likely received PSA tests from other providers.
Keywords: Costs and cost analysis, Health services, Medicare, Health policy, Economic models, Cancer screening,
Geriatrics, Prostate cancer, Prostate-specific antigen, Healthcare providers
Background
The United States (U.S.) Preventive Services Task Force
[1], the American Cancer Society [2], the American
College of Physicians [3], and the American Urological
Association [4] recommend against the use of the
prostate-specific antigen (PSA) test to detect prostate can-
cer in men aged 75 years and older or those with a life ex-
pectancy of less than 10 to 15 years, because the risk of
harms outweighs potential benefits. Nevertheless, screen-
ing rates for PSA tests for prostate cancer detection re-
main high in clinical practice in older men in the U.S. [5–
10]. The major harm is from over-diagnosis: detecting and
treating cancers that otherwise would not have become
clinically apparent in the patient’s lifetime [5].
A high level of variability in the PSA testing rates at
the primary care provider (PCP) level in men aged 75 or
older was recently found [5, 11]. Which PCP a man saw
accounted for 27 % of the variance in whether he re-
ceived PSA screening. One consequence of PSA testing
is increased payments, not only for the PSA test but also
for subsequent tests and treatments stimulated by an ab-
normal PSA level. Several groups have described the
downstream trajectories after PSA testing in various set-
tings utilizing nationally representative data [12–15].
These studies showed that more and frequent PSA test-
ing in older men can increase the number of men who
undergo prostate biopsy [13], increase their risk of
trans-rectal ultrasound [15], increase their likelihood of
being diagnosed with low or intermediate risk prostate
cancer [12] and increase their odds of receiving prostate
cancer treatments - either surgery, radiation or hormo-
nal therapy [12, 13, 15]. The downstream reimbursement
implications of prostate cancer screening in fee-for-
service Medicare were estimated to be 72 % of the over-
all annual PSA screening expenditures of 447 million US
dollars in 2009 [14].
Based on these findings, we sought to estimate the
magnitude of downstream testing, treatments and Medi-
care public insurance payments for prostate cancer em-
anating from high-testing PCPs compared to low-testing
PCPs. Our overall study approach was to identify PCPs
in Texas, U.S., whose PSA testing rates in 2009 in men
aged 75 or older were significantly higher or significantly
lower than the mean rates for all Texas PCPs. We then
divided our patient cohort into two groups: men seeing
PCPs who were high users of PSA tests and men seeing
PCPs who were low users of PSA tests. We then
followed all male patients of those PCPs who were aged
75 and older to assess the amount of prostate cancer re-
lated tests and treatments they received in 2010 and
2011. In assigning PCPs to high or low PSA testing
groups, only PSA testing ordered by that PCP was
assessed, but in assessing prostate cancer related tests
and treatments in 2010–2011, we included all tests and
treatments ordered by any provider. The purpose of our
study was to explore the rates of tests and treatments
and Medicare payments for care in older men cared by
high PSA test rate PCPs in comparison to low test rate
PCPs.
Methods
We had a data user agreement (#21332) with U.S. Cen-
ters for Medicare and Medicaid Services to use 100 %
Texas Medicare data to conduct studies on the quality
of cancer screening in Texas. Informed consent was not
required as our study was a secondary analysis of de-
identified patient data, including any procedure codes
that were used. Our study was exempt from review by
the Institutional Review Board of the University of Texas
Medical Branch, Galveston, Texas, U.S. (#10-175, Evalu-
ation of Cancer Screening Practices).
Study design, setting, & data source
This was a retrospective cohort study of men aged 75 years
and older in Texas, U.S. who had a PCP with a PSA test
rate significantly higher or lower than the mean. In the
U.S., Medicare is a federally funded public health insur-
ance program for its citizens aged 65 years and older.
We used the 100 % Medicare Claims and Beneficiary
Summary Files for the state of Texas (2006–2011),
Outpatient Standard Analytic files (OUTSAF), Carrier
files and Medicare Provider Analysis and Review (MED-
PAR) files.
Construction of PCP groups with high or low PSA testing
rate
We first selected men aged 75 or older as of 1/1/2009
who had Medicare Parts A and B with no health main-
tenance organization (HMO) enrollment between 2006
and 2009, to identify PCPs with high or low PSA test
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rates. We excluded patients with a history of prostate
neoplasm in 2006–2008 as identified by the Inter-
national Classification of Disease, 9th, Revision, Clin-
ical Modification (ICD-9-CM) diagnostic codes: 185
(prostate cancer), V10.46 (personal history of prostate
cancer), 222.2 (benign neoplasm of prostate), 233.4
(prostate carcinoma in situ) and 236.5 (neoplasm of
uncertain behavior of prostate). We also excluded
those who had prostatectomy in this period, identified
by ICD-9-CM procedure codes 60.2-60.6 and Current
Procedure Terminology (CPT) codes: 55801, 55810,
55812, 55815, 55821, 55842 and 55845. These men
with an identifiable PCP in 2009 were then selected.
For PCPs, we selected only those (2,169) whose patient
panels included at least 20 men (87,351 men). PSA
tests ordered by these PCPs in 2009 were assessed and
the PSA testing rate for each PCP was estimated using
a two-level generalized linear hierarchical model,
adjusting for patient characteristics. Among the 2,169
PCPs, 550 (25.4 %) had a PSA testing rate significantly
higher than the mean, and 638 (29.4 %) had a signifi-
cantly lower rate. Among the 87,351 men, 25,280
(28.9 %) were cared for by the high PSA rate PCPs in
2009 and 26,910 (30.8 %) by the low PSA rate
PCPs (Refer to Additional file 1).
Construction of patient sample for assignment to high or
low PCP group
Study participants
For the study cohort, men aged 75 years or older as of
1/1/2010, with Medicare Parts A and B and without
HMO enrollment- between 2007 and 2011, and without
history of prostate cancer in 2007–2009 were selected.
Their PCPs in 2009 were identified and men who were
cared for by the high PSA rate PCPs (N = 22,853) and
those cared for by the low PSA rate PCPs (N = 23,929)
were selected for this study (Refer to Additional file 2).
Data analysis was performed in 2013–2014.
Patient characteristics
Patient demographic data obtained from the 2010
Beneficiary Summary File included age, sex and race/
ethnicity. The number of comorbidities was assessed
from the Medicare claims for physician services, out-
patient and inpatient services from the Carrier File,
OUTSAF and MEDPAR Files for 2009 [16-18]. Medic-
aid eligibility status was obtained from the 2010 Benefi-
ciary Summary File. Area of residence was classified as
metropolitan, non-metropolitan or rural as defined by
the U.S. Department of Agriculture [19]. The education
level at the zip code of residence was obtained from the
2011 American Community Survey estimates from the
U.S. Census Bureau.
Comparisons of tests, treatments and healthcare services
among patients within high versus low PCP group
The number and proportion of men in the high or low
PCP testing group who had any PSA screening test,
prostate biopsy, ultrasound, imaging or prostate cancer
treatment (including radiation therapy, prostatectomy or
androgen deprivation therapy) during the 2-year study
period were determined using MEDPAR, Carrier and
OUTSAF files. The codes used to identify claims with
such procedures are included in a Additional file 3. Two
types of office visits were assessed: 1) visits specific for
prostate cancer to any provider and 2) any visits to an
urologist. Office visits were identified using CPT codes
99201–99205 and 99211–99215 from the Carrier and
OUTSAF files. Visits specific for prostate cancer were
defined by office visit claims with a primary diagnosis of
prostate cancer (ICD-9-CM 185) in the Carrier files or
in OUTSAF files. The Medicare reimbursements for
prostate cancer care among beneficiaries were computed
by summing the payments for PSA tests, biopsies, ultra-
sounds, imaging, prostate cancer treatments and Evalu-
ation and Management (E&M) office visits specific for
prostate cancer to any provider for each man across the
two PCP groups.
Statistical analysis
The Pearson Chi-Square tests were used to examine the
differences in patient characteristics of those cared for by
PCPs with high and low PSA testing rates. Differences be-
tween percentages in each outcome between PCPs with
high and low PSA testing rates were also determined by
Chi-Square tests. Logistic models adjusted for age, ethni-
city, comorbidity, Medicaid eligibility, urban or rural resi-
dence and education at the zip code level were used to
determine the effect of PCP type (high vs. low PSA testing
rate) on each test, treatment and service type. The differ-
ences in annual Medicare payments for tests, treatments
and E&M services were determined using the Wilcoxon
rank-sum test.
Modeling annual Medicare payments for patients
The differences in annual prostate specific payments
and total Medicare payments were evaluated for pa-
tients by PCP group using the Wilcoxon rank-sum test.
A generalized gamma model with log link function was
used [20–22], adjusted for the aforementioned patient
characteristics to estimate the mean annual prostate
specific payments and the mean annual total payments
for patients in the two PCP groups. The PCP was
included as a random effect variable in our model. All
patient characteristics were included in our model as
categorical variables. We included twenty-nine comorbidi-
ties from year 2009 as dichotomous (yes/no) variables. A
two-part model was used to estimate prostate specific
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payments because 33 % of the study subjects had no pay-
ments. In part I, a logistic regression model was utilized to
determine the probability of having any payments. In part
II, the mean annual payment per patient for those who in-
curred any payment, was modeled using a generalized
gamma regression. The estimates from the two-part
model and the generalized gamma model were similar
(Table 3). SAS statistical software (Version 9.3; SAS Insti-
tute, Inc., Cary, NC) was used for all analyses. Two-sided
tests of statistical significance were employed and p-values
less than 0.05 were considered statistically significant.
Results
Among the 2,169 PCPs with at least 20 men aged 75 or
older in their patient panels in 2009, 550 (25.4 %) had
PSA test rates significantly above the mean and 638
(29.4 %) had PSA test rates significantly below the mean.
The mean testing rate was 33.5 %, adjusted for patient
characteristics, including age, race and ethnicity, Medic-
aid eligibility, rural–urban residence, education at the
zip code level and comorbidity. Patients who were 75 or
older in 2010 were selected to compare the differences
in prostate cancer related tests and treatments between
the high versus low PSA test rate PCP groups.
Table 1 presents the characteristics of the patients in
these two groups. A higher percentage of patients cared
for by PCPs with high PSA testing rates lived in metro-
politan areas and had high education levels. Table 1 pre-
sents the percent of men in each group who underwent
PSA testing in either 2010 or 2011, and the percent of
men with any PSA test ordered by the man’s PCP or by
another provider. Of the men with low-testing PCPs,
33.3 % had PSA tests ordered by those PCPs, com-
pared to 71.8 % of men with high-testing PCPs. When
considering PSA screening ordered by a provider other
than a patient’s PCP, 32.8 % of men with low testing
PCPs and 25.4 % with high testing PCPs underwent
PSA screening.
Table 2 presents the number, rate and odds of prostate
cancer related tests, treatments received and outpatient
visits by the men cared for by PCPs with either high or
low PSA testing rates. These tests, treatments and visits
were not necessarily performed by the men’s PCPs.
Compared to the men with low testing PCPs, men with
high testing PCPs were more likely to be diagnosed with
prostate cancer as more of them had an office visit with
prostate cancer as the primary diagnosis (1.8 % vs. 1.5 %,
p = 0.017). The multivariable model adjusted for patient
characteristics shows that men with high testing PCPs
were 21 % more likely to have such outpatient visits.
Men with high testing PCPs, in comparison to low test-
ing PCPs, had higher rates of receiving PSA tests (82.7 %
vs. 57.7 %, p < 0.001), prostate biopsies (2.4 % vs. 2.1 %,
p = 0.022), ultrasound (3.4 % vs. 2.9 %, p = 0.002) and
radiation treatment for prostate cancer (0.7 % vs. 0.5 %, p
= 0.013). The multivariable model adjusted for patient
characteristics shows that men cared for by high PSA rate
PCPs were more likely to receive a PSA test (OR = 3.64,
95 % CI 3.48-3.80), a biopsy (OR = 1.16, 95 % CI 1.02–
1.31), an ultrasound (OR = 1.19, 95 % CI 1.07–1.32) and
any radiation treatment (OR = 1.31, 95 % CI 1.03–1.66)
than men cared for by low PSA rate PCPs. The proportion
of patients without any prostate cancer associated
utilization was significantly lower for men cared for by
high PSA rate PCPs compared to those cared for by low
PSA rate PCPs (OR = 0.27, 95 % CI: 0.26-0.29).
Table 3 summarizes the annual Medicare payments in
patients for prostate cancer related tests, treatments and
health services by high or low testing PCPs. Compared
to the low-testing PCPs, the Medicare payments for men
with high testing PCPs were significantly higher in PSA
tests, biopsies, ultrasounds, radiation and E&M services
for prostate cancer. However, the payment made for rad-
ical prostatectomy and androgen deprivation therapy did
not differ between these two groups. According to the
adjusted model, the estimated annual prostate cancer as-
sociated Medicare payment in men who saw PCPs with
a high PSA test rate was $80.63 (95 % CI 78.13–83.22),
compared to $55.01 (95 % CI 53.34–56.73) for men who
saw PCPs with a low rate of testing.
Discussion
In this study, we compare the frequency of prostate can-
cer specific care and associated costs that are incurred
in older men cared for by high versus low PSA test rate
PCP groups. For every 10,000 men cared for by high
PSA test rate PCPs, an additional 2,495 men got PSA
screened, an additional 31 men underwent prostate bi-
opsy, an additional 51 received ultrasound, an additional
18 received radiation treatment and an additional 28
outpatient visits were made for prostate cancer related
concerns to any provider. Extrapolating these findings to
the 448,530 men [23] in Texas, U.S. aged 75 years and
over and multiplying them by the proportion of men
cared for by high PSA test rate PCPs (28.9 %), an esti-
mated 3 million U.S. dollars can be saved annually in
prostate specific health care expenses if older men in
Texas with high PSA test rate PCPs saw PCPs with low
PSA test rates.
After accounting for patient characteristics, the ad-
justed annual prostate specific payment in the high PSA
test PCP group was $25.62 higher than in the low test
group, an approximate 47 % increase. The overall Medi-
care payment per beneficiary did not differ significantly
between these two PCP groups (their CIs overlapped).
The 47 % increase in downstream testing roughly paral-
lels the 43 % increase in men receiving PSA tests in
those cared for by high vs. low testing PCPs (82.7 % vs
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57.7 %, Table 2). Men cared for by high testing PCPs
were more likely to be diagnosed with prostate cancer.
However, the magnitude is small (1.8 % vs. 1.5 %,
Table 2). This might contribute to the small difference
in downstream diagnostic tests and treatments between
men in these two groups.
Our estimates of annual prostate cancer associated pay-
ments are likely underestimates of the total payments for
prostate cancer care in older men. Our study estimated
the direct medical costs of downstream prostate cancer
care from the U.S. Medicare’s perspective. Indirect costs
of care due to productivity loss from the patient’s and
caregivers’ time, and travel costs for patients and their
families could not be measured using the claims data.
Such indirect costs are likely to be substantially more than
direct costs alone. In addition, Medicare reimbursements
Table 1 Patient characteristics overall and by PCPs with high or low PSA ordering rates
N (%)
Characteristics Overall High rank PCP Low rank PCP p-value
Overall 46782 (100) 22853 (100) 23929 (100)
Any PSA testing 32697 (69.9) 18889 (82.7) 13808 (57.7) <0.001
Any PSA testing ordered by patient’s PCP 24378 (52.1) 16403 (71.8) 7975 (33.3) <0.001
Any PSA testing ordered by provider other than patient’s PCP 13649 (29.2) 5810 (25.4) 7839 (32.8) <0.001
Age Years)
75–79 22024 (47.1) 10900 (47.7) 11124 (46.5) 0.008
80–84 14958 (32.0) 7287 (31.9) 7671 (32.1)
≥ 85 9800 (20.9) 4666 (20.4) 5134 (21.5)
Ethnicity
Non-Hispanic White 38169 (81.6) 18673 (81.7) 19496 (81.5) <0.001
Black 1346 (2.9) 586 (2.6) 760 (3.2)
Hispanic 6614 (14.1) 3209 (14.0) 3405 (14.2)
Others 653 (1.4) 385 (1.7) 268 (1.1)
Elixhauser Comorbidity
0 6110 (13.1) 2896 (12.7) 3214 (13.4) 0.027
1 12846 (27.5) 6230 (27.3) 6616 (27.6)
2 11988 (25.6) 5889 (25.8) 6099 (25.5)
3 7098 (15.2) 3559 (15.6) 3539 (14.8)
≥ 4 8740 (18.7) 4279 (18.7) 4461 (18.6)
Medicaid Eligible
Yes 4813 (10.3) 2328 (10.2) 2485 (10.4) 0.481
No 41969 (89.7) 20525 (89.8) 21444 (89.6)
Urban/Rural
Metro 34536 (73.8) 17847 (78.1) 16689 (69.7) <0.001*
Non-Metro 11279 (24.1) 4730 (20.7) 6549 (27.4)
Rural 960 (2.1) 272 (1.2) 688 (2.9)
Unknown 7 (0.0) 4 (0.0) 3 (0.0)
Percent of persons in zip code 25 or older with high school education or higher
Q1: ≤ 74 % 11859 (25.3) 5514 (24.1) 6345 (26.5) <0.001*
Q2: 74–83 % 11503 (24.6) 5009 (21.9) 6494 (27.1)
Q3: 83–90 % 11815 (25.3) 5829 (25.5) 5986 (25.0)
Q4: 90–100 % 11529 (24.6) 6485 (28.4) 5044 (21.1)
Unknown 76 (0.2) 16 (0.1) 60 (0.3)
PCP primary care provider, PSA prostate specific antigen
Q1 quartile 1, Q2 quartile 2, Q3 quartile 3, Q4 quartile 4
p-value was calculated using chi-square test between high- and low-PSA-rate PCP groups
*The unknown was excluded for chi-square test
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do not reflect payments by other payers, out-of-pocket
patient or family expenses or co-payments.
There are several other limitations to our study. First,
we excluded men with any evidence of prostate cancer
diagnosis or treatment in the prior 3 years. However,
given the high prostate cancer survival rate, our study
cohort might include some patients who have received
and completed prostate cancer treatment before this
period. When selecting subjects aged 75 or older with a
10-year continuous enrollment for the look back period,
Table 3 Medicare payments for prostate cancer care in patients by PCPs with high or low PSA ordering rates
Medicare payment Annual payment, mean ± STD (median, Q1-Q3) Difference
(High-Low)
p-value
High (N = 22853) Low (N = 23929)
PSA tests 21.04 ± 18.35 (13.18, 12.95–26.13) 13.51 ± 17.95 (12.95, 0.00–26.13) 7.53 <0.001
Biopsies 3.05 ± 23.85 (0.00, 0.00–0.00) 2.86 ± 24.30 (0.00, 0.00–0.00) 0.19 0.022
Ultrasounds 1.76 ± 10.22 (0.00, 0.00–0.00) 1.49 ± 9.53 (0.00, 0.00–0.00) 0.27 0.001
Imaging 1.29 ± 17.29 (0.00, 0.00–0.00) 1.00 ± 14.59 (0.00, 0.00–0.00) 0.29 0.109
Radiation 52.87 ± 715.37 (0.00, 0.00–0.00) 35.78 ± 576.59 (0.00, 0.00–0.00) 17.09 0.011
Radical prostatectomy 2.39 ± 139.61 (0.00, 0.00–0.00) 1.60 ± 76.29 (0.00, 0.00–0.00) 0.79 0.116
Androgen deprivation therapy 5.49 ± 77.92 (0.00, 0.00–0.00) 5.03 ± 74.10 (0.00, 0.00–0.00) 0.46 0.597
E&M services for prostate cancer 2.83 ± 26.24 (0.00, 0.00–0.00) 2.25 ± 25.25 (0.00, 0.00–0.00) 0.58 0.026
E&M services from urologists 35.39 ± 70.54 (0.00, 0.00–52.84) 34.78 ± 71.51 (0.00, 0.00–52.28) 0.61 0.353
Prostate cancer associated payment 90.72 ± 802.43 (13.18, 12.95–26.13) 63.51 ± 642.59 (12.95, 0.00–26.13) 27.21 <0.001





Adjusted annual payment - GLM model (95 % CI)
Prostate cancer associated payment 80.63 (78.13–83.22) 55.01 (53.34–56.73) 25.62
Overall Medicare payment 8358.94 (8233.38–8486.42) 8377.71 (8254.63–8502.64) −18.77
PSA prostate specific antigen, E&M evaluation and management, PCP primary care provider, PSA prostate specific antigen, Q1 quartile 1, Q3 quartile 3, GLM
generalized linear model with log link function
p-values were calculated by Wilcoxon test. Medicare payments are in 2011 U.S. dollars. The prostate cancer associated payment was also analyzed by a two-part
model which generated similar estimates (the difference between patients with high and low PSA rate PCPs was $25.32)
Table 2 Outcomes for prostate cancer care in patients by PCPs with a high or low PSA ordering rate
Outcomes Test/Treatment/Service type N (%) Odds Ratio
(95 % CI), High
vs. Low
High (N = 22853) Low (N = 23929)
Diagnostic Test
PSA test 18889 (82.7) 13808 (57.7) 3.64 (3.48, 3.80)
Biopsy 546 (2.4) 497 (2.1) 1.16 (1.02, 1.31)
Ultrasound 774 (3.4) 688 (2.9) 1.19 (1.07, 1.32)
Imaging 196 (0.9) 174 (0.7) 1.18 (0.96, 1.45)
Treatment
Any treatment for prostate cancer 270 (1.2) 258 (1.1) 1.10 (0.93, 1.31)
Radiation 159 (0.7) 124 (0.5) 1.31 (1.03, 1.66)
Radical prostatectomy 18 (0.1) 30 (0.1) 0.67 (0.37, 1.21)
Androgen deprivation therapy 166 (0.7) 162 (0.7) 1.11 (0.89, 1.38)
Health Services
Outpatient office visit for prostate cancer 413 (1.8) 365 (1.5) 1.21 (1.05, 1.39)
Outpatient office visit to urologists 8087 (35.4) 8434 (35.2) 0.98 (0.94, 1.02)
Without any prostate cancer associated utilization listed above 3915 (17.1) 10046 (42.0) 0.27 (0.26, 0.29)
The average adjusted rate of ordering PSA test in 550 high test rate PCPs in 2009 was 63.0 ± 10.4. The average adjusted rate of ordering PSA test in 638 low test
rate PCPs in 2009 was 7.6 ± 5.2. The odds ratio was estimated by logistic models adjusted for age, ethnicity, comorbidity, Medicaid eligibility, urban or rural
residence and education at the zip code level. 80 (0.17 %) men with unknown urban/rural residence or education information were excluded. Prostate cancer
associated utilization did not include outpatient office visits to urologists as the reason for the visit was not limited to prostate cancer
CI confidence interval, PCP primary care provider, PSA prostate specific antigen
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we found almost 70 % of prostate cancer patients could
be captured using data from a 3-year look back period.
Second, the interpretation of the analysis is based on
the assumption that PSA testing was used for screening
rather than diagnostic purposes. While patients with
prior ICD codes specific for prostate diseases were ex-
cluded, some PSA testing may still have been used for
evaluating symptoms, such as hematuria and urinary
obstruction, rather than screening. Third, patient pref-
erences influence the receipt of PSA tests, particularly
in older men [24–26]. It is possible that patients with
similar preferences aggregate with specific PCPs.
Fourth, the cohort of patients and physicians in this
study was limited to Texas, U.S. Texas is a large state
in the U.S. with recognizable geographic variations in
health service utilization and health care costs [27–29],
and higher PSA screening rates have been reported for
southern states [29]. Therefore, the study results may
not be generalizable to PCPs of older men in other
states. The study results may not be applicable to youn-
ger men or to those outside the Medicare fee-for-
service reimbursement system, such as those in the
Veteran Affairs or those in HMOs in the U.S. The
strengths of this study include use of 100 % Medicare
claims data for Texas which allowed for a representa-
tive large sample of all Texas Medicare enrollees.
Conclusions
We found substantial variation in the frequency of
prostate cancer specific tests, treatments, services, and
associated costs in men with PCPs with high versus
low PSA testing rates. Future studies are needed to ex-
plore the drivers of differences between the high ver-
sus low PSA testing PCPs and their dynamics with
urologists and other providers in the delivery of effi-
cient cancer care [30], and to examine the effect of
payment reform in balancing the perspectives of vari-
ous actors in health decision making in the light of the
current U.S. Patient Protection and Affordable Care
Act [31, 32].
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